Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BR1019-3
- Development stage
- Unknown
- Lead developer
- Boryung
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
BR1019-3 is an experimental pharmaceutical agent studied as part of a combination therapy with other related compounds (notably BR1019 and BR1019-2) for the treatment of essential hypertension and type 2 diabetes mellitus. It is being developed by Boryung Pharmaceutical. The drug has been evaluated in phase 1 clinical trials to assess its pharmacokinetics and safety profile when administered alone or in combination with other agents from the same series. The precise mechanism of action, molecular target, and chemical structure have not been publicly disclosed as of June 2025[1][2][5].
- Other names
- BR1019-3BR-1019-3BR 1019-3
Beyond the preview
Go deeper on BR1019-3.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BR1019-3.